Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Aph(3′)-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia

Aki Okazaki, Matthew B. Avison
Aki Okazaki
Bristol Centre for Antimicrobial Research and Evaluation, Department of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Avison
Bristol Centre for Antimicrobial Research and Evaluation, Department of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: matthewb.Avison@bris.ac.uk
DOI: 10.1128/AAC.00795-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We report the characterization of an intrinsic, chromosomally carried aph(3′)-IIc gene from Stenotrophomonas maltophilia clinical isolate K279a, encoding an aminoglycoside phosphotransferase enzyme that significantly increases MICs of kanamycin, neomycin, butirosin, and paromomycin when expressed in Escherichia coli. Disruption of aph(3′)-IIc in K279a results in decreased MICs of these drugs.

Stenotrophomonas maltophilia is an emerging nosocomial pathogen. Isolates display intrinsic resistance to many commonly prescribed antimicrobials, particularly β-lactams and aminoglycosides. They can also evolve broad-spectrum resistance to a cross section of other drugs that have been used to treat infections (6). Intrinsic β-lactam resistance in S. maltophilia is due to two β-lactamase enzymes, L1 and L2, which are produced at higher levels following β-lactam challenge (3, 4, 7). Aminoglycoside resistance in S. maltophilia is less well understood. An aminoglycoside acetyltransferase, AAC(6′)-Iz, is produced by some isolates, conferring reduced susceptibility to amikacin, netilmicin, sisomicin, and tobramycin (11, 12). However, isolates are also frequently resistant to aminoglycosides known to be substrates of aminoglycoside phosphotransferase (APH) enzymes, for example, kanamycin and neomycin, suggesting that an aph gene might be present in the S. maltophilia genome (12). In order to test this possibility, we used the APH(3′)-IIa amino acid sequence encoded on Tn5 (5) to search for genes encoding similar proteins in the genome of S. maltophilia clinical isolate K279a, which has been extensively characterized in this laboratory (2-4, 7, 8). tBLASTn searches (1) of the K279a genome sequence (http://www.sanger.ac.uk/cgi-bin/blast/submitblast/s_maltophilia ) revealed a single significant hit, and the amino acid sequence of the putative protein was used to perform a BLASTp search (1) against the NCBI database. The protein falls into the APH(3′)-II class according to sequence similarity, being 50% identical to both the Tn5 APH(3′)-IIa and the Pseudomonas aeruginosa chromosomally encoded APH(3′)-IIb (9). The putative S. maltophilia APH(3′)-II shares >45% identity with putative APH(3′)-II proteins encoded on the chromosomes of various environmental organisms, including Burkholderia spp. (though not pathogenic species), Rhizobium etli, Mesorhizobium loti, and Sinorhizobium meliloti. In contrast, it is only 34% identical to the archetypal APH(3′)-I encoded on Tn903 (13).

The S. maltophilia K279a aph(3′)-II gene was PCR amplified using the PCR protocol described previously (2) and the primers aph-F (5′-ATGGAAGCACCCAATCC-3′) and aph-R (5′-TGCTGGCGTGGGACAACA-3′). The 1,102-bp amplicon was TA cloned into the pBAD-TOPO expression vector (Invitrogen, Leek, Holland) according to the manufacturer's instructions, and recombinant plasmid carrying correctly oriented aph was transformed into Escherichia coli DH5α (Invitrogen). As a negative control, DH5α::pBAD was used. MICs of a variety of aminoglycosides were determined against the recombinant E. coli strains in the presence and absence of arabinose (1%, wt/vol), which induces expression of the cloned gene (Table 1). Clearly, of those aminoglycosides tested, K279a aph expression confers greatly reduced susceptibility to kanamycin, neomycin, butirosin, and paromomycin, as is expected given its predicted molecular type (4).

MICs of all aminoglycosides tested, including APH(3′)-II substrates, against S. maltophilia isolate K279a are high. We confirmed by PCR using the primers previously defined (12) that isolate K279a carries an S. maltophilia aac(6′)-Iz gene (11, 12) encoding resistance to (of those aminoglycosides tested by us) amikacin, sisomicin, and tobramycin (data not shown). Total RNA purification and reverse transcription-PCR, both performed using the protocol described previously (8), but with the reverse transcription-PCR primers aph-RTF (5′-AGGAACAGGGACAACCCG-3′) and aph-RTR (5′-CCAGGTCTTCATGATCGG-3′), confirmed that isolate K279a expresses aph under normal laboratory growth conditions (data not shown). Accordingly, to test whether aph is a true determinant of intrinsic aminoglycoside resistance in K279a, we disrupted the gene in an otherwise wild-type background. We did this by first PCR amplifying aph in two nonoverlapping fragments, the 5′ proximal of which had a HindIII site inserted at its 3′ end and the 3′ proximal of which had a HindIII site inserted at its 5′ end. The primer pairs used (with the HindIII sites underlined) were aph-delF (5′-CAGTAATGGACCTGTGGGC-3′) and aph-HindR (5′-AAGCTTTGAAGTCGGAAGTGA-3′) and aph-HindF (5′-AAGCTTGTAGCGGCATGCCATC-3′) and aph-delR (5′-CACCATCAGGTTCGGCAA). The two resultant amplicons were digested with HindIII, mixed, and ligated together to produce a mutant aph allele with a 111-bp internal deletion (i.e., a frameshift). This so-called aphFS allele was cloned into the suicide gene replacement vector pEXTc (10) and the recombinant plasmid mobilized into S. maltophilia K279a through conjugation with E. coli SM10. Selection for gene replacement was performed as described previously (8, 10), and mutants were confirmed by PCR and sequencing. MICs of a variety of aminoglycosides against K279a and the aphFS mutant are presented in Table 1. These data show that aph contributes to intrinsic kanamycin, neomycin, butirosin, and paromomycin resistance in S. maltophilia, confirming the result of the E. coli heterologous host experiment. We can therefore conclude with confidence that the newly identified aph(3′)-II gene from S. maltophilia encodes a protein that modifies kanamycin, neomycin, butirosin, and paromomycin, thus contributing to the resistance of S. maltophilia isolates to these drugs and, together with the previously described AAC(6′)-Iz, resistance to all aminoglycosides tested except gentamicin. Because this represents the third characterized example of an APH(3′)-II enzyme, we have named it APH(3′)-IIc.

In S. maltophilia K279a, aph(3′)-IIc appears to be a chromosomal gene. There is no evidence of linked mobile genetic elements or of a difference in guanine-cytosine content indicative of the gene being acquired recently by S. maltophilia (data not shown). To confirm whether this is the case, we used PCR to test for the presence of homologues of the aph(3′)-IIc gene in a collection of previously characterized clinical S. maltophilia isolates collected from Europe and North, South, and Central America (7). PCR using the aph-F and aph-R primer set (above) gave strong PCR products of the correct size when genomic DNA from 50% of the isolates was used as template; some other isolates gave very weak bands (data not shown). We therefore made another primer set to amplify a 344-bp region of the core of K279a aph(3′)-IIc beginning 218 bp downstream of its start. The primers were aphint-F (5′-AGGAACAGGGACAAACCG-3′) and aphint-R (5′-CCAGGTCTTCATGATCGG-3′). Intriguingly, the use of this second primer set gave appropriately sized PCR products only when the template used was genomic DNA from those isolates that did not give a strong positive PCR product with the full-length primer set (data not shown). The exception to this rule is K279a itself, which gave a product with both primer sets. Therefore, these data suggest that while a homologue of the aph(3′)-IIc gene is present in all the isolates tested, supporting our conclusion that this is an intrinsic resistance gene in S. maltophilia, there is some sequence heterogeneity. This was not unexpected given the degree of genetic variability known to occur among different S. maltophilia isolates (3, 7, 8).

View this table:
  • View inline
  • View popup
TABLE 1.

MICs of various aminoglycosides against recombinant E. coli DH5α producing or not producing S. maltophilia APH(3′)-IIc and against S. maltophilia K279a and an aphFS derivative

ACKNOWLEDGMENTS

This work was funded by the Biotechnology and Biological Sciences Research Council and the British Society for Antimicrobial Chemotherapy. Determination of the S. maltophilia K279a genome sequence was funded by the Wellcome Trust.

FOOTNOTES

    • Received 1 July 2006.
    • Returned for modification 12 August 2006.
    • Accepted 23 October 2006.
  • Copyright © 2007 American Society for Microbiology

REFERENCES

  1. 1.↵
    Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol.215:403-410.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Avison, M. B., C. J. von Heldreich, C. S. Higgins, P. M. Bennett, and T. R. Walsh. 2000. A TEM-2 β-lactamase encoded on an active Tn1-like transposon in the genome of a clinical isolate of Stenotrophomonas maltophilia. J. Antimicrob. Chemother.46:879-884.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Avison, M. B., C. S. Higgins, C. J. von Heldreich, P. M. Bennett, and T. R. Walsh. 2001. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother.45:413-419.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Avison, M. B., C. S. Higgins, P. J. Ford, C. J. von Heldreich, T. R. Walsh, and P. M. Bennett. 2002. Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia. J. Antimicrob. Chemother.49:387-389.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Beck, E., G. Ludwig, E. A. Auerswald, B. Reiss, and H. Schaller. 1982. Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5. Gene19:327-336.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Denton, M., and K. G. Kerr. 1998. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev.11:57-80.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Gould, V. C., A. Okazaki, and M. B. Avison. 2006. β-Lactam resistance and β-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships. J. Antimicrob. Chemother.57:199-203.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Gould, V. C., and M. B. Avison. 2006. SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J. Antimicrob. Chemother.57:1070-1076.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Hächler, H., P. Santanam, and F. H. Kayser. 1996. Sequence and characterization of a novel chromosomal aminoglycoside phosphotransferase gene, aph(3′)-IIb, in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.40:1254-1256.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Hoang, T. T., R. R. Karkhoff-Schweizer, A. J. Kutchma, and H. P. Schweizer. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene212:77-86.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Lambert, T., M.-C. Ploy, F. Denis, and P. Courvalin. 1999. Characterization of the chromosomal aac(6′)-Iz gene of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother.43:2366-2371.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Li, X.-Z., L. Zhang, G. A. McKay, and K. Poole. 2003. Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J. Antimicrob. Chemother.51:803-811.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Oka, A., H. Sugisaki, and M. Takanami. 1981. Nucleotide sequence of the kanamycin resistance transposon Tn903. J. Mol. Biol.147:217-226.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Aph(3′)-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia
Aki Okazaki, Matthew B. Avison
Antimicrobial Agents and Chemotherapy Dec 2006, 51 (1) 359-360; DOI: 10.1128/AAC.00795-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aph(3′)-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Aph(3′)-IIc, an Aminoglycoside Resistance Determinant from Stenotrophomonas maltophilia
Aki Okazaki, Matthew B. Avison
Antimicrobial Agents and Chemotherapy Dec 2006, 51 (1) 359-360; DOI: 10.1128/AAC.00795-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

aminoglycosides
Drug Resistance, Multiple, Bacterial
Kanamycin Kinase
Stenotrophomonas maltophilia

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596